Neuphoria Therapeutics (NASDAQ:NEUP) Downgraded to “Neutral” Rating by HC Wainwright

HC Wainwright cut shares of Neuphoria Therapeutics (NASDAQ:NEUP) from a buy rating to a neutral rating in a report issued on Friday, MarketBeat.com reports.

Other analysts have also recently issued reports about the stock. Zacks Research upgraded shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $21.00.

Neuphoria Therapeutics Stock Performance

NEUP stock opened at $4.73 on Friday. The stock has a market cap of $25.50 million, a P/E ratio of -1.07 and a beta of 0.72. The firm has a 50 day simple moving average of $4.72 and a 200 day simple moving average of $4.38. Neuphoria Therapeutics has a 52 week low of $3.64 and a 52 week high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last posted its earnings results on Tuesday, May 19th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. Sell-side analysts predict that Neuphoria Therapeutics will post -4.07 EPS for the current year.

Institutional Investors Weigh In On Neuphoria Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. AdvisorShares Investments LLC lifted its position in Neuphoria Therapeutics by 15.8% during the 1st quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock worth $632,000 after buying an additional 21,173 shares in the last quarter. Diadema Partners LP lifted its position in Neuphoria Therapeutics by 133.1% during the 4th quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock worth $194,000 after buying an additional 28,548 shares in the last quarter. Ikarian Capital LLC acquired a new position in Neuphoria Therapeutics during the 4th quarter worth about $184,000. ADAR1 Capital Management LLC acquired a new position in Neuphoria Therapeutics during the 4th quarter worth about $116,000. Finally, FNY Investment Advisers LLC acquired a new position in Neuphoria Therapeutics during the 4th quarter worth about $102,000. Institutional investors and hedge funds own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.